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A B S T R A C T   
9-kDa granulysin is a protein expressed into the granules of human cytotoxic T lymphocytes (CTL) and natural 
killer (NK) cells. It has been shown to exert cytolysis on microbes and tumors. We showed previously that 9-kDa 
granulysin exerted cell death by apoptosis in vitro on hematological tumor cell lines and also on cells from B-cell 
chronic lymphocytic leukemia (B-CLL) patients. In addition, we have shown the anti-tumor efficiency of gran-
ulysin as a single agent in two in vivo models of human tumor development in athymic mice, the MDA-MB-231 
mammary adenocarcinoma and the NCI-H929 multiple myeloma, without signs of overt secondary effects by 
itself. In this work, we have tested recombinant 9-kDa granulysin in an in vivo and especially aggressive model of 
melanoma development, xenografted UACC62 cells in athymic mice. Recombinant granulysin was administered 
once UACC62-derived tumors were detectable and it substantially retarded the in vivo development of this 
aggressive tumor. We could also detect apoptosis induction and increased NK cell infiltration inside granulysin- 
treated tumor tissues. These observations are especially interesting given the possibility of treating melanoma by 
intra-tumor injection.   
Introduction 
Granulysin is a protein that exhibits two isoforms, of 9 and 15 kDa 
molecular weight [1]. The 9-kDa isoform is expressed inside the gran-
ules of activated human cytotoxic T lymphocytes (CTL) and natural 
killer (NK) cells and shows cytolytic activity against microbes and tu-
mors [1]. The 15-kDa isoform is not cytotoxic and rather induces 
monocyte differentiation to dendritic cells [2]. It has been described that 
each one of these isoforms localize to different types of granules, and 
that their requirements for degranulation are different [3]. The main 
physiological function of the 9-kDa cytotoxic isoform is the killing of 
intracellular bacteria such as M. Tuberculosis in concert with perforin 
[4]. Granulysin is able to kill other bacteria [5], fungi such as Crypto-
coccus Neoformans [6], viruses such as Varicella Zoster [7], acting also in 
the immune response against leprosy [8]. Recently, it has been sug-
gested that its mechanism of action against bacterial and protozoan 
parasites is through the generation of pores on their surface, facilitating 
lysis by granzyme B [9,10]. 
Several groups have demonstrated that recombinant 9-kDa gran-
ulysin is able to induce cell death on tumor cells [1,11,12]. Granulysin 
induces cell death mainly by apoptosis, although in certain cell types, a 
necroptotic component can be also detected [11,13]. Recombinant 
granulysin-induced apoptosis is initiated by its interaction with plasma 
membrane, altering cellular [Ca2+] homeostasis, and inducing in this 
way a net increase in mitochondrial reactive oxygen species (ROS). 
These biochemical events cause finally the loss of mitochondrial mem-
brane potential and the concomitant release of cytochrome c and 
apoptosis-inducing factor (AIF) from the intermembrane space of 
mitochondria, initiating the mitochondral apoptotic pathway [11,12, 
14]. Remarkably, using cytotoxic cells from granulysin transgenic mice 
crossed with perforin or granzyme B-deficient mice, Saini et al. 
demonstrated that granulysin, acting in concert with perforin activated 
a different apoptotic pathway, dependent on endoplasmic reticulum 
stress and caspase-7 activation [15]. 
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In any case, recombinant granulysin could be a good candidate for 
tumor therapy. Granulysin was able to kill in vitro the acute T cell leu-
kemia Jurkat, human multiple myeloma cell lines and also leukemic 
cells from B-cell chronic lymphocytic leukemia (B-CLL) patients, but it 
was not toxic against healthy peripheral blood mononuclear cells 
(PBMC) [11]. In addition, granulysin transgenic mice demonstrated 
higher resistance to syngeneic tunor development than wild-type mice 
[16]. More recently, we have demonstrated the efficiency of recombi-
nant granulysin in xenotransplantation models of human tumors in 
athymic mice, the mammary adenocarcinoma MDA-MB231 and the 
multiple myeloma NCI-H929 [17]. We showed that granulysin 
anti-tumoral action in these models correlated with apoptosis induction 
in the tumor tissue and with a prominent NK cell infiltration, indicating 
that granulysin-induced tumor cell death in vivo could be immunogenic. 
In the same study, we showed the lack of secondary effects of granulysin 
alone. In that study, human tumors were injected subcutaneolsy in mice, 
and treatments were performed by intratumoral injection. This type of 
treatment could be difficult to perform in internal tumors, in which a 
systemic treatment would be better indicated. 
Melanoma is the most aggressive form of skin cancer. Melanoma 
outcome is dependent on their detection at early stages, since surgical 
excision of the primary tumor has over a 95% success rate at stages I/II 
[18]. However, melanoma lesions can remain unnoticeable for long 
periods and being detected only at stage IV, characterized by dissemi-
nation (metastasis) to multiple organs. Recent advances in immuno-
therapy of melanoma, mainly the blocking of immune checkpoint 
molecules such as CTLA-4 or PD-1 has given new hope to patients [19]. 
Although melanoma outcomes have clearly improved, with the median 
overall survival of patients with advanced-stage melanoma from around 
9 months before 2011 to 2 years in 2017 [20], not all patients respond in 
the same way and many of them experiment relapses. Hence, new 
treatments alone or in combination with already used chemo-, radio- or 
immunotherpay could still improve the situation of melanoma patients. 
Melanoma is a type of tumor that could be suitable for treatment by 
intratumoral injection in the clinic and that has not been previoulsy 
tested as a target for granulysin therapy. In the present work, we have 
tested recombinant granulysin in a xenotransplant model of the 
aggressive human melanoma UACC62 in athymic mice, obtaining 
promising results. 
Material and methods 
Cell culture 
Jurkat and NCI-H929 cells were cultured in RPMI 1640 medium 
supplemented with 5% FCS and penicillin/streptomycin (Pan Biotech, 
Aidenbach, Germany) and GlutaMAX (Invitrogen, Barcelona), at 37ºC 
and 5% CO2. SKMEL103, UACC62 and A549 cell lines were cultured in 
DMEM medium (PAN Biotech GmbH) supplemented with 10% fetal 
bovine serum (FBS, Sigma). Cell lines were tested for mycoplasma 
contamination by PCR. SKMEL103 and UACC62 melanoma cell lines 
were kindly provided by Dr. María Soledad Soengas, CNIO, Madrid, 
Spain 
Recombinant granulysin expression and purification 
Recombinant granulysin was produced in E. coli and purified as 
described in  [11,17], using an on-column renaturation approach 
following the protocol described in [21]. Protein purity was checked by 
SDS-PAGE in 12% polyacrylamide gels and Coomassie blue staining and 
also by immunoblot with specific rabbit polyclonal anti-9 kDa gran-
ulysin antibody, gift of Drs. Alan Krensky and Carol Clayberger, 
Northwestern University, Chicago, USA. The content of LPS was deter-
mined before and after removal of endotoxin using the ToxinEraser 
Endotoxin Removal Kit from Genscript, as indicated in [17]. In the stock 
solutions, the concentrations were 22 EU/ml before removal and 11 
EU/ml after removal. The volume injected in mice was of 50 µl, so the 
total endotoxin injected was around 0,5 EUs. 
In vitro granulysin cytotoxicity assays 
For in vitro assays, cells were incubated with granulysin or with the 
same amount of PBS in control wells at 37ºC and then cell death was 
analyzed by PS exposure and loss of membrane integrity. These pa-
rameters were analyzed at the same time by flow cytometry using 
Annexin-V-FITC (BD Biosciences, Madrid) and 7AAD (Inmunostep, 
Salamanca, Spain), respectively, and results analyzed using a FACSCa-
libur (BD, Madrid). 
Determination of calreticulin exposure after granulyin treatment 
Cells in suspension were directly treated with a 30 µM dose of GRNLY 
for approximately 24 h, while adherent cells were treated approximately 
12–24 h later to allow time for the cells to adhere to the surface of the 
well. Then a centrifugation was carried out to eliminate the supernatant 
and proceed to the labeling. The cells were labeled with an anti- 
calreticulin mAb (Invitrogen, Madrid) and with 7-AAD to be able to 
select and analyze only 7-AAD negative cells to ensure that only living 
cells that expose calreticulin on their surface are analyzed. An isotype 
control was also carried out. Specifically, 50 ng of 7-AAD per well and 5 
μg per 106 cells of the anti-calreticulin or of the isotype control mAb 
were added in PBS buffer with 5% FBS and incubated for 30 min at 4◦C 
in darkness before analyzing the results by flow cytometry. To perform 
the histogram, 10,000 cell events with negative 7-AAD labeling were 
analyzed. 
In vivo experiments in athymic mice 
In vivo experiments were performed using six-week-old athymic 
males of the Swiss nu/nu strain (Charles River, Barcelona). Animal 
experimentation was performed according to the European recommen-
dations on animal ethics and the University of Zaragoza Animal Exper-
imentation Ethical Commission previously approved the housing and 
experimental protocols, with permission number PI17/16. 
1 × 106 or 2,5 × 105 UACC62 melanoma cells were injected s.c. in 10 
nude mice in each experiment. When tumor volume had arrived to 0.1 
cm3 (15 days or less), mice were divided in two groups, the control 
group and the group treated with granulysin, being n = 5 for each 
experimental group. In the granulysin-treated group, 44 μg of granulysin 
in 50 μl of phosphate buffered saline (PBS) were injected every 2 days for 
10 times in each mouse. In the control group, mice were injected in the 
same way with 50 μl of PBS alone. Tumor growth was analyzed every 2 
days by measuring tumor size with a precision caliper. To calculate the 




where A is the width and L the length of the tumor. At day 22 after the 
initiation of the treatments, mice were sacrificed following ethical rules 
and tumors were excised. Tumor tissues were stored in 10% buffered 
formalin until examination in histological studies. 
Histological studies on tumor sections 
Hematoxylin-eosin histological staining 
Tissue was fixed in 4% formaldehyde and embedded in paraffin. 5- 
μm sections were cut from the tissue blocks and deparaffinized by im-
mersion in xylene twice for 5 min each. After that, tissue sections were 
rehydrated by immersion in decreasing concentrations of ethanol. Then, 
immersing in GILL II Hematoxylin for 3 min stained nuclei. Afterwards, 
cell cytoplasm was stained by immersing in 0.5% of eosin, which con-
tains 0.2% of glacial acetic acid, for 3 min. Finally, sections were 
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dehydrated by immersion in solutions with ascending alcohol percent-
ages. All sections were cleaned by xylene, dried and mounted on glass 
coverslips with DPX. 
Fluorescence study of apoptotic nuclei and immunohistochemistry for 
detection of activated caspase-3 and NK1.1 staining 
Tissue sections 5-μm thick were deparaffinated, rehydrated and 
stained by immersing in GILL II Hematoxylin followed by eosin staining. 
For the study of apoptotic nuclei, tissue sections were stained with DAPI 
Fluoromont-G (EMS, Madrid) for 10 min and detected in a fluorescence 
microscope (E600/E400, Nikon) equipped with a digital photography 
machine (DXM1200F, Nikon). 
The expression of activated caspase-3 was investigated by immuno-
histochemistry using a rabbit polyclonal anti-human caspase-3 antibody 
(Cell Signaling, Barcelona), which recognizes the active, cleaved 
caspase-3 form. After blocking with 5% horse serum diluted in PBS for 
1hr at room temperature, sections were incubated at 4 ◦C in humid 
chambers with the anti-caspase-3 antibody at 1/150 dilution for 1hr 
followed by ready to use secondary anti-rabbit antibody (Vector Labo-
ratories, Peterborough, UK) for 30 min. As a chromogenic substrate, 
3,3′-Diaminobenzidine (DAB; Agilent, Madrid) was used, followed by 
hematoxylin counterstaining. Appropriate negative control stainings 
were also performed. For the study of NK cell infiltration in tumor tissue, 
sections were stained with a rabbit polyclonal antibody anti-human 
NKp46 from Biorbyt (Cambridge, UK), and revealed in the same way 
as indicated for caspase-3 activation. Isotype control staining were also 
performed, showing no substantial signal. 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism 4.0 pro-
gram (GrandPath Software Inc). Statistical significance was evaluated 
by using Student t-test for non-paired variants, considering a p <0.05 
value as significant. 
Results 
In vitro cytotoxic activity of recombinant granulysin on human melanoma 
cell lines 
In previous studies, we have demonstrated the high sensitivity of the 
Jurkat T cell leukemia to recombinant granulysin cytotoxicity [11]. We 
tested the in vitro toxicity of recombinant granulysin on two human 
melanoma cell lines, SK-MEL103 and UACC62, and comparatively also 
on Jurkat cells. SKMEL103 cells are p53 and BRAF wt, but exhibit the 
Q16R mutation in N-Ras and PTEN deletion; UACC62 cells are p53 and 
N-Ras wt, but exhibit the V600E mutation in BRAF, together with p16 
and PTEN deletion, making it a specially aggressive tumor [22]. 
As shown in Fig. 1, while Jurkat cells were very sensitive to 50 µM 
granulysin after 24 h of incubation, SK-MEL103 cells showed low 
sensitivity, and UACC62 cells showed a significant level of sensitivity, 
although not as high as Jurkat cells. In principle, mutations in UACC62 
cells would make it a more aggressive tumor than SKMEL103, but, at the 
same time, it resulted more sensitive to granulysin. Granulysin has been 
shown to be inactive against normal T lymphocytes, and the higher or 
lower sensitivity of several multiple myeloma cell lines to granulysin 
correlated rather with the ratio between pro-apoptotic and anti- 
apoptotic long members of the Bcl-2 family [11]. 
In vivo granulysin treatment experiments on UACC62-induced tumors 
Due to its higher in vitro sensitivity to recombinant granulysin, and 
given that it easily generates tumors in immune-deficient mice [22], we 
chose the UACC62 cell line to perform xenograft experiments in athymic 
mice, essentially as described in our previous work on mammary 
adenocarcinoma and multiple myeloma [17]. 
1 × 106 UACC62 cells were injected subcutaneously (s.c.) in groups 
of athymic mice and treatments started when tumor volume arrived to 
100 mm3. Tumor growth was extremely aggressive, growing to a size of 
100 mm3 in 2 weeks or less. Mice were then divided into two groups, the 
group treated with granulysin and the control group. In the granulysin 
group, 44 μg of granulysin suspended in 50 µl PBS was injected intra- 
tumorally every 2 days for a total of 10 injections. In the control 
group, 50 µl PBS was injected following the same temporal schedule. 
After the 10 injections, mice were sacrificed and tumors resected. As 
shown in Fig 2A, the external, apparent mean tumor volume was not 
greatly affected by treatment with recombinant granulysin in this 
aggressive tumor model. However, when tumors were resected, and the 
inflammatory surroundings eliminated, the mean size of granulysin- 
treated melanomas were significantly reduced with respect to the con-
trol group (Fig 2B). The mean tumor size was reduced from 5036 mm3 in 
the control group to 2830 mm3 in the treated group, meaning a 44% 
reduction, that arrived to be statistically significant (P = 0.05 in the 
Student’s t-test). 
Given the aggressiveness of the tumor, we performed a second set of 
experiments, injecting s.c. 2,5 × 105 tumor cells instead of 1 × 106, 
while following a similar protocol as above. As shown in Fig 3A, in these 
experimental conditions, the external volume of the tumor was reduced 
by granulysin treatment throughout the experiment, with a reduction at 
the time of sacrifice from a mean of 7325 mm3 in the control group to 
4282 mm3 in the treated group, a 42% decrease. However, due to the 
high SD in the control group, differences were not statistically signifi-
cant. When the size of the tumors was measured after resection, the 
reduction was greater, from a mean size of 4247 mm3 in the control 
Fig. 1. In vitro granulysin-induced death of Jurkat, SK-MEL103 and UACC62 
cells. Jurkat, SK-MEL103 (SK) or UACC62 cells (UACC) were incubated (black 
bars, GRNL) or not (white bars, Control) with 50 µM recombinant granulysin 
during 24 h. A, cell death was estimated using Trypan blue staining. B, 
apoptotic cell death was determined by detection of phosphatidylserine expo-
sure by staining with Annexin-V-FITC. Results are the mean ± SD of 3 different 
experiments. 
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group to 1964 mm3 in the treated group, a 54% reduction, which was 
statistically significant (Fig 3B). These data indicate that intra-tumor 
administration of recombinant granulysin retards tumor growth in the 
aggressive UACC62 melanoma xenograft. 
H&E and DAPI staining, caspase-3 activation and NK cell infiltration on 
resected UACC62-derived tumors 
H&E staining was performed on paraffin-embedded tumor samples. 
Regarding tumors obtained from the experiment shown in Fig. 2, tumors 
in the control group showed a compact tissue organization, forming 
nested structures, sometimes separated by connective tissue walls (Fig 
4A, upper left panel), and sometimes extremely well irrigated (Fig 4A, 
upper middle panel). Hemorrhagic areas could be also observed in these 
tumors, accompanied by the presence of defined regions containing cells 
with heavily stained, picnotic nuclei (Fig 4A, upper right panel). In the 
case of tumors treated with granulysin, although it could be observed 
regions with compact structure, formed by healthy, well irrigated cells 
(e.g., Fig 4A lower left panel), the most frequent tissue aspect, especially 
in the internal part of the tumor, was a less compact structure, with 
frequent gaps, and with a predominance of cells with heavily stained, 
picnotic nuclei (Fig 4A, lower middle and right panels). In H&E stainings 
made on tumors obtained in the experiment shown in Fig. 3, we can 
observe again in the controls the indicated nested and well irrigated 
structures (Fig 4B, upper panels), while the aspect of the tumors treated 
with granulysin were characterized by the presence of gaps and of areas 
devoid of nucleated cells, probably made of collagen or other extracel-
lular matrix proteins. The presence of picnotic nuclei was also clearly 
detected in these treated tumors (Fig 4B, lower panels). 
To analyze nuclear apoptotic features in vivo we stained tumor tissue 
sections with DAPI. Control tumor samples show the typical nuclear 
staining of living cells, while in treated tumors, it could be easily 
detected the higher intensity of labeling, due to chromatin condensa-
tion, together with the very frequent observation of fragmented nuclei, 
especially clear in the high magnification pictures, and indicated with 
arrows (Fig 5A). In addition, there were also observed cells with pe-
ripheral nuclear condensed chromatin (indicated with circles in Fig 5A), 
typical of apoptosis-inducing factor (AIF)-mediated cell death, that our 
Fig. 2. Granulysin treatment of nude mice bearing UACC62 human melanoma cancer xenografts. 1 × 106 UACC62 melanoma cells were injected s.c. in 10 nude 
mice. When tumor volume had arrived to 0.1 cm3 mice were divided in two groups, Ctrl (white bars) and GRNL-treated (black bars), n = 5. Mice in the GRNL group 
received intra-tumor injections of GRNL and mice in the Ctrl group of PBS every 2 days for 10 times and then mice were sacrificed. A, data are the mean ± SD of the 
tumor volume in each group of the study. B, data show the tumor volumes after resection. *, P = 0.05. 
Fig. 3. Granulysin treatment of nude mice 
bearing UACC62 human melanoma cancer xe-
nografts. 2.5 × 105 UACC62 melanoma cells 
were injected s.c. in 10 nude mice. When tumor 
volume had arrived to 0.1 cm3 mice were 
divided in two groups, Ctrl (white bars) and 
GRNL-treated (black bars), n = 5 for each 
experimental group. Mice in the GRNL group 
received intra-tumor injections of GRNL at 44 μg 
in 50 µl of PBS every 2 days for 10 times and 
then mice were sacrificed. Mice in the Ctrl group 
received injections of 50 µl PBS with the same 
time schedule. A, data are the mean ± SD of the 
tumor volume in each group of the study. B, 
data show the tumor volumes after resection in 
the two experimental groups described. *, P <
0.05.   
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group demonstrated previously was implicated in granulysin-induced 
cell death [14]. 
To confirm apoptosis induction in vivo, we performed anti-caspase 3 
immunostaining on tumor samples. For that, we used an antibody that 
detects the active, cleaved form of caspase-3. As shown in Fig. 5B, 
peroxidase staining was clearly observed in tumor samples obtained 
from treated tumor samples, both at low and high magnification, while it 
was absent in tumor samples from control mice. 
In our previous study [17], we also showed that granulysin treatment 
induced the infiltration of NK cells in the tumor tissue. Athymic mice 
used in these studies are deficient in T cells, but other cells characteristic 
of the innate immune response, such as neutrophils, macrophages or NK 
cells are normally expressed. Therefore, we studied NK cell infiltration 
in the melanoma model using immunostaining with an anti-NKp46 
antibody. 
We could not detect intratumoral staining of NK cells in tumors from 
control, untreated mice (Fig 6, upper panels). In the case of tumors from 
granulysin-treated mice, although NK infiltration was not massive and 
there were tumor zones devoid of peroxidase labeling, we could detect 
in almost all samples analyzed some cells clearly stained with peroxi-
dase, indicating some NK cell infiltration due to the intratumoral 
granulysin treatment (Fig 6, lower panels). In the image obtained at a 
higher magnification (Fig 6, lower right panel), a group of NK cells is 
close to a blood vessel, indicating NK cell extravasation in the proximity 
of the tumor mass. 
Determination of calreticulin exposure upon granulysin treatment in tumor 
cell lines 
The observed NK cell infiltration in the tumor mass could indicate 
that granulysin is inducing an immunogenic type of cell death. To 
further study this possibility, we perfomed in vitro assays to determine if 
granulysin treatment was able to induce calreticulin (CRT) exposure on 
the surface of tumor cells, one of the most important markers of this type 
of cell death. As shown in Fig. 7, granulysin increased CRT exposure in 
two different types of cells. In the NCI-H929 multiple myeloma, which 
grows in suspension, the increase was of 40%, while in the lung carci-
noma A549, which grow as adherent cells, similar to the UACC62 mel-
anoma, the increase was of 27%. 
Discussion 
In the initial characterization paper of granulysin, it was demon-
strated that recombinant 9-kDa granulysin was able to kill tumor cells in 
the absence of perforin [1]. Afterwards, it was demonstrated that 
granulysin expression correlated with good prognosis in different types 
of cancer patients [23-26]. Although the antitumor role of endogenous 
9-kDa granulysin has not been clearly demonstrated, the recombinant 
molecule could be tested as an anti-tumor agent. In previous in vitro 
studies from our group, it was demonstrated its activity against the 
human acute lymphoblastic leukemia (ALL) Jurkat [14,27], against 
several human multiple myeloma cell lines [11] and, most importantly, 
against primary leukemic cells from B-cell chronic lymphocytic leuke-
mia (B-CLL) patients [11]. Subsequently, we also showed the in vivo 
potential of recombinant granulysin in xenotransplant models of human 
breast adenocarcinoma MDA-MB-231 and human multiple myeloma 
NCI-H929 [17]. In this study, we showed that intratumoral injection of 
recombinant granulysin induced apoptosis in the in vivo treated tumors, 
and also the infiltration of NK cells. 
A recent concept in cancer treatment is that of immunogenic tumor 
Fig. 4. H&E staining in histological sections of UACC62-derived tu-
mors. A, representative images of resected UACC62-derived tumors 
from the control group or from the granulysin-treated group (Grnl) of 
the experiment depicted in Fig 2 are shown. B, representative images 
of resected UACC62-derived tumors from the control group or from the 
granulysin-treated group (Grnl) of the experiment depicted in Figs 3 
are shown. Tissue sections were stained with hematoxylin and eosin, 
as indicated in Materials and Methods, and photographed at a 100X 
magnification in all images.   
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cell death. Some cytotoxic drugs normally used in chemotherapy, such 
as anthracyclines, are able to kill cancer cells in such a way that they 
promote a subsequent antitumor immune response [28,29]. We have 
confirmed in the melanoma model described in this work that gran-
ulysin generate some type of immunogenic tumor cell death in vivo, 
resulting in intratumoral NK cell recruitment. This effect could be due in 
part to the presence of small amounts of endotoxin in the granulysin 
preparation, although we have used an endotoxin-removal kit. Howev-
er, in our previous study [17], we demonstrated that the in vivo antitu-
moral effect of recombinant granulysin was not dependent on the higher 
or lower amount of endotoxin in the preparations. In addition, we have 
demonstrated in several tumor cell models, that granulysin is able to 
induce calreticulin exposure on their plasma membrane, one of the 
hallmarks of immunogenic cell death [29]. 
Results presented in this work suggest that intra-tumor administra-
tion of granulysin could be used as a novel anti-melanoma treatment. Of 
course, more pre-clinical and translational research would be needed to 
ascertain this. The results obtained in the melanoma model are espe-
cially interesting for two reasons. First, the intratumoral injection, 
although difficult to perform in internal tumors, could be easily adapted 
to melanoma treatment. Second, given the in vitro and in vivo immuno-
genic potential of granulysin-induced cell death, observed here and in 
our previous study [17] associated with its capacity to recruit NK cells, 
granulysin can be used to transform non-immunogenic tumors in 
immunogenic [30], and then combine with immunotherapy regimens, 
such as immune checkpoint inhibitor blockers, which are achieving 
impressive results in melanoma patients [31]. It should be noted than in 
the athymic mice model, only NK cells are immune anti-tumor effectors, 
but that in immunocompetent settings, this immunogenicity would 
probably extend to specific anti-tumoral cytotoxic T lymphocytes. 
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Fig 7. Induction of calreticulin exposure upon 
granulysin treatment. Calreticulin exposure was 
analyzed by flow cytometry on the surface of 
H929 and A549 cells after treatment with 30 
µM granulysin for 24 h. Solid black histograms, 
labeling of control cells, non-treated with 
granulysin, with an anti-calreticulin mAb con-
jugated with FITC; cyan histograms, labeling of 
cells treated with granulysin with the anti- 
calreticulin mAb; discontinuous histograms, 
labeling of cells with an isotype control mAb 
conjugated with FITC.   
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